drugset / Trial / NCT01055145

Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients

NCT01055145

Phase 3 Terminated 182 enrolled Seoul National University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Fluoroquinolone is a one of the most important drugs for treatment of multidrug-resistant TB (MDR-TB). Among them, levofloxacin and moxifloxacin has been used most widely. However, there is no study to directly compare the efficacy of levofloxacin and moxifloxacin among MDR-TB patients. The investigators will compare the efficacy of levofloxacin and moxifloxacin through a prospective multicenter randomized open label phase III trial.

Timeline

Start
2010-03
Primary completion
2012-07
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levofloxacin Small molecule 750 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications